Conversion of Prostate Adenocarcinoma to Small Cell Carcinoma-Like by Reprogramming

Journal of Cellular Physiology

Volumn 231, Issue 9, 2016, Pages 2040-2047

  Borges, Gisely T ^a,b,c   Vêncio, Eneida F ^a,b,c   Quek, Sue Ing ^a,b   Chen, Adeline ^a,b   Salvanha, Diego M ^d   Vêncio, Ricardo Z N ^d   Nguyen, Holly M ^a   Vessella, Robert L ^a,e   Cavanaugh, Christopher ^b   Ware, Carol B ^b   Troisch, Pamela ^f   Liu, Alvin Y ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTOME;

ARTICLE; CANCER CELL LINE; CANCER GROWTH; CANCER STEM CELL; CELL TRANSFORMATION; GENE EXPRESSION; GENE SEQUENCE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; SMALL CELL CARCINOMA; ADENOCARCINOMA; CELL DIFFERENTIATION; CYTOLOGY; DRUG SCREENING; GENE EXPRESSION PROFILING; GENETICS; HOMEOBOX; INDUCED PLURIPOTENT STEM CELL; MALE; METABOLISM; NUCLEAR REPROGRAMMING; PATHOLOGY; PHYSIOLOGY; PROCEDURES; PROSTATE; PROSTATE TUMOR; TUMOR CELL LINE;

ADENOCARCINOMA; CARCINOMA, SMALL CELL; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELLULAR REPROGRAMMING; GENE EXPRESSION PROFILING; GENES, HOMEOBOX; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MALE; PROSTATE; PROSTATIC NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84959162569     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.25313     Document Type: Article

References (43)

1. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. 2004. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100:3983-3988.
2. American Cancer Society. 2015. Cancer facts and figures, 2015. Atlanta: American Cancer Society.
3. Bayart E, Cohen-Haguenauer O. 2013. Technological overview of iPS induction from human adult somatic cells. Curr Gene Ther 13:73-92.
4. Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, Sboner A, Esgueva R, Pflueger D, Sougnez C, Onofrio R, Carter SL, Park K, Habegger L, Ambrogio L, Fennell T, Parkin M, Saksena G, Voet D, Ramos AH, Pugh TJ, Wilkinson J, Fisher S, Winckler W, Mahan S, Ardlie K, Baldwin J, Simons JW, Kitabayashi N, MacDonald TY, Kantoff PW, Chin L, Gabriel SB, Gerstein MB, Golub TR, Meyerson M, Tewari A, Lander ES, Getz G, Rubin MA, Garraway LA. 2011. The genomic complexity of primary human prostate cancer. Nature 470:214-220.
5. Bernhardt M, Galach M, Novak D, Utikal J. 2012. Mediators of induced pluripotency and their role in cancer cells-Current scientific knowledge and future perspectives. Biotechnol J 7:810-821.
6. Brasil, Ministério da Saúde. 2010. Câncer de próstata. INCA. (http://www2.inca.gov.br/).
7. Cancer Genome Atlas Network. 2012. Comprehensive molecular portraits of human breast tumours. Nature 490:61-70.
8. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. 2005. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65:10946-10951.
9. Colman A, Dreesen O. 2009. Induced pluripotent stem cells and the stability of the differentiated state. EMBO Rep 10:714-721.
10. Corey E, Vessella RL. 2007. Xenograft models of human prostate cancer. In: Chung LW, Isaacs WB, Simons JW, editors. Prostate cancer: Biology, genetics and the new therapeutics. Totowa, NJ: Humana Press. pp 3-31.
11. Cox ME, Deeble PD, Lakhani S, Parsons SJ. 1999. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: Implications for prostate cancer progression. Cancer Res 59:3821-3830.
12. Egevad L, Mazzucchelli R, Montironi R. 2012. Implications of the international society of urological pathology modified Gleason grading system. Arch Pathol Lab Med 136:426-434.
13. Epstein JI, Amin MB, Beltran H, Lotan TL, Mosquera JM, Reuter VE, Robinson BD, Troncoso P, Rubin MA. 2014. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol 38:756-767.
14. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. 2010. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893-2917.
15. Ho ME, Quek S, True LD, Morrissey C, Corey E, Vessella RL, Dumpit R, Nelson PS, Maresh EL, Mah V, Alavi M, Kim SR, Bagryanova L, Horvath S, Chia D, Goodglick L, Liu AY. 2013. Prostate cancer cell phenotypes based on AGR2 and CD10 expression. Mod Pathol 26:849-859.
16. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. 1974. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 112:798-801.
17. Kumar A, White TA, MacKenzie AP, Clegg N, Lee C, Dumpit RF, Coleman I, Ng SB, Salipante SJ, Rieder MJ, Nickerson DA, Corey E, Lange PH, Morrissey C, Vessella RL, Nelson PS, Shendure J. 2011. Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc Natl Acad Sci USA 108:17087-17092.
18. Li H, Chen X, Calhoun-Davis T, Claypool K, Tang DG. 2008. PC3 human prostate carcinoma cell holoclones contain self-renewing tumor-initiating cells. Cancer Res 68:1820-1825.
19. Liu AY, True LD, LaTray L, Nelson PS, Ellis WJ, Vessella RL, Lange PH, Hood LE, van den Engh G. 1997. Cell-cell interaction in prostate gene regulation and cytodifferentiation. Proc Natl Acad Sci USA 94:10705-10710.
20. Liu AY, Vêncio RZN, Page LS, Ho ME, Loprieno MA, True LD. 2012. Bladder expression of CD cell surface antigens and cell-type-specific transcriptomes. Cell Tissue Res 348:589-600.
21. Mosquera JM, Beltran H, Park K, MacDonald TY, Robinson BD, Tagawa ST, Perner S, Bismar TA, Erbersdobler A, Dhir R, Nelson JB, Nanus DM, Rubin MA. 2013. Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia 15:1-10.
22. Newcomb LF, Thompson IM, Boyer HD, Brooks JD, Carroll PR, Cooperberg MR, Dash A, Ellis WJ, Fazli L, Feng Z, Gleave ME, Kunju P, Lance RS, McKenney JK, Meng MV, Nicolas MM, Sanda MG, Simko J, So A, Tretiakova MS, Troyer DA, True LD, Vakar-Lopez F, Virgin J, Wagner AA, Wei JT, Zheng Y, Nelson PS, Lin DW. 2016. Outcomes of active surveillance for clinically localized prostate cancer in the prospective, multi-institutional Canary PASS cohort. J Urol 95:313-320.
23. Oster G, Lamerato L, Glass AG, Richert-Boe KE, Lopez A, Chung K, Richhariya A, Dodge T, Wolff GG, Balakumaran A, Edelsberg J. 2013. Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: A 15-year study in two large US health systems. Support Care Cancer 21:3279-3286.
24. Oudes AJ, Roach JC, Walashek LS, Eicher LJ, True LD, Vessella RL, Liu AY. 2005. Application of Affymetrix array and massively parallel signature sequencing for identification of genes involved in prostate cancer progression. BMC Cancer 5:86.
25. Oudes AJ, Campbell DS, Sorensen CM, Walashek LS, True LD, Liu AY. 2006. Transcriptomes of human prostate cells. BMC Genomics 7:92.
26. Pascal LE, Oudes AJ, Petersen TW, Goo YA, Walashek LS, True LD, Liu AY. 2007. Molecular and cellular characterization of ABCG2 in the prostate. BMC Urol 7:6.
27. + prostate tumor-associated stromal cells involves potential organ-specific genes. BMC Cancer 9:317.
28. Pascal LE, Vêncio RZN, Goo YA, Page LS, Shadle CP, Liu AY. 2009b. Temporal expression profiling of the effects of secreted factors from prostate stromal cells on embryonal carcinoma stem cells. Prostate 69:1353-1365.
29. Pascal LE, Vêncio RZN, Page LS, Liebeskind ES, Shadle CP, Troisch P, Marzolf B, True LD, Hood LE, Liu AY. 2009c. Gene expression relationship between prostate cancer cells of Gleason 3, 4 and normal epithelial cells as revealed by cell type-specific transcriptomes. BMC Cancer 9:452.
30. Pascal LE, Vêncio RZN, Vessella RL, Ware CB, Vêncio EF, Denyer G, Liu AY. 2011. Lineage relationship of prostate cancer cell types based on gene expression. BMC Medical Genomics 4:46.
31. Qiu W, Hu W, Sridhar A, Opeskin K, Fox S, Shipitsin M, Trivett M, Thompson ER, Ramakrishna M, Gorringe KL, Polyak K, Haviv I, Campbell IG. 2008. No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas. Nat Genet 40:650-655.
32. Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng FY, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, Mostaghel EA, Cheng HH, Mulcahy H, True LD, Plymate SR, Dvinge H, Ferraldeschi R, Flohr P, Miranda S, Zafeiriou Z, Tunariu N, Mateo J, Perez-Lopez R, Demichelis F, Robinson BD, Schiffman M, Nanus DM, Tagawa ST, Sigaras A, Eng KW, Elemento O, Sboner A, Heath EI, Scher HI, Pienta KJ, Kantoff P, de Bono JS, Rubin MA, Nelson PS, Garraway LA, Sawyers CL, Chinnaiyan AM. 2015. Integrative clinical genomics of advanced prostate cancer. Cell 161:1215-1228.
33. Saar M, Zhao H, Nolley R, Young SR, Coleman I, Nelson PS, Vessella RL, Peehl DM. 2014. Spheroid culture of LuCaP 147 as an authentic preclinical model of prostate cancer subtype with SPOP mutation and hypermutator phenotype. Cancer Lett 351:272-280.
34. Sharpe B, Beresford M, Bowen R, Mitchard J, Chalmers AD. 2013. Searching for prostate cancer stem cells: Markers and methods. Stem Cell Rev 9:721-730.
35. Sun C, Liu YK. 2011. Induced pluripotent cancer cells: Progress and application. J Cancer Res Clin Oncol 137:1-8.
36. Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, Page ST, Coleman IM, Nguyen HM, Sun H, Nelson PS, Plymate SR. 2010. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 120:2715-2730.
37. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. 2007. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131:861-872.
38. Tan HL, Sood A, Rahimi HA, Wang W, Gupta N, Hicks J, Mosier S, Gocke CD, Epstein JI, Netto GJ, Liu W, Isaacs WB, De Marzo AM, Lotan TL. 2014. Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. Clin Cancer Res 20:890-903.
39. Tummala R, Nadiminty N, Lou W, Zhu Y, Gandour-Edwards R, Chen HW, Evans CP, Gao AC. 2013. Lin28 promotes growth of prostate cancer cells and activates the androgen receptor. Am J Pathol 183:288-295.
40. Vêncio EF, Nelson AM, Cavanaugh C, Ware CB, Miller DG, Garcia JC, Vêncio RZN, Loprieno MA, Liu AY. 2011. Embryonal carcinoma cell induction of miRNA and mRNA changes in co-cultured prostate stromal fibromuscular cells. J Cell Physiol 226:1479-1488.
41. Vêncio EF, Pascal LE, Page LS, Denyer G, Wang AJ, Ruohola-Baker H, Zhang S, Wang K, Galas DJ, Liu AY. 2012. Reprogramming of prostate cancer-associated stromal cells to embryonic stem-like. Prostate 72:1453-1463.
42. Young SR, Saar M, Santos J, Nguyen HM, Vessella RL, Peehl DM. 2013. Establishment and serial passage of cell cultures derived from LuCaP xenografts. Prostate 73:1251-1262.
43. Yuan TC, Veeramani S, Lin MF. 2007. Neuroendocrine-like prostate cancer cells: Neuroendocrine transdifferentiation of prostate adenocarcinoma cells. Endocr Relat Cancer 14:531-547.